Future studies will be needed to disentangle these contributing factors, to test if p‐tau 217 and 231 epitopes are more sensitive to intermediate ADNC than p‐tau181, and test utility of different p‐tau epitopes in LBSD to detect αSyn+AD. The gene discussed is MAPT; the disease is Alzheimer disease.